Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-26T02:30:00.306Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment with Interferon Beta-1b Improves Quality of Life in Multiple Sclerosis

Published online by Cambridge University Press:  02 December 2014

G.P. Rice ,
J. Oger ,
P. Duquette ,
G.S. Francis ,
M. Bélanger ,
S. Laplante  and
J.F. Grenier
G.P. Rice
Affiliation:
MS Clinic at the University Hospital, London ON
J. Oger
Affiliation:
MS Clinic at the University of BC, Vancouver Hospital & Health Care Center/Division of Neurology, BC
P. Duquette
Affiliation:
MS Clinic at the CHUM, Campus Notre-Dame, Montreal, QC
M. Bélanger
Affiliation:
MS Clinic at the Montreal Neurological Institute, Montreal, QC, and Berlex Canada Inc., Montreal QC
S. Laplante
Affiliation:
MS Clinic at the Montreal Neurological Institute, Montreal, QC, and Berlex Canada Inc., Montreal QC
J.F. Grenier
Affiliation:
MS Clinic at the Montreal Neurological Institute, Montreal, QC, and Berlex Canada Inc., Montreal QC
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The Canadian Burden of Illness Study Group reported that the quality of life (QoL) of multiple sclerosis (MS) patients falls drastically, early in the disease. With disability progression, the physical functioning scales of the Short Form 36 (SF-36) showed further decreases in QoL. The objective of this study is to describe the QoL of MS patients treated with interferon beta-1b (IFNB-1b) and to compare it to the QoL observed in a group of patients who had not been treated with IFNB-1b.

Methods:

Treated patients were prospectively recruited and were seen at their regular visit to the MS clinic. They self-completed the SF-36 questionnaire and their QoL was described and retrospectively compared to that of historical controls.

Results:

When IFNB-1b treated patients were compared to historical control patients with the same relapsing forms of MS, the treated patients with an Expanded Disability Status Scale (EDSS) score lower than 3.0 had a significantly better QoL. This was significant for four of the eight SF-36 domains: Physical Function (+22%, p=0.0102), Role-Physical (+100%, p=0.0022), General Health (+27%, p=0.0070) and Social Function (+19%, p=0.0287). The average QoL difference was 8% in the EDSS 3.0-6.0 group and 10% in the EDSS >6 group.

Conclusion:

Patients with relapsing forms of MS treated with IFNB-1b have better QoL than patients who are not treated, especially those with an EDSS < 3.0.

Résumé

RÉSUMÉContexte:

Le Groupe canadien sur le fardeau de la maladie (Canadian Burden of Illness Study Group) a rapporté que la qualité de vie (QV) des patients atteints de sclérose en plaques (SEP) chute de façon drastique tôt au cours de la maladie. Avec la progression de l’invalidité, les échelles de fonctionnement physique de la Forme courte d’échelle à 36 questions (SF-36) ont montré une diminution plus marquée de la QV. Le but de cette etude était de décrire la QV de patients atteints de SEP traités par l’interféron bêta-1b (IFNB-1b) et de la comparer à la QV d’un groupe de patients n’ayant pas reçu ce traitement.

Méthodes:

Les patients traités ont été recrutés prospectivement et ont été vus à leur visite régulière à la clinique de SEP. Ils ont complété un questionnaire autoadministré, le SF-36, et leur QV a été décrite et comparée rétrospectivement à celle de contrôles historiques.

Résultats:

Quand les patients traités par le IFNB-1b ont été comparés aux contrôles historiques souffrant des memes formes rémittentes de SEP, les patients traités qui avaient un score plus bas que 3.0 à l’échelle d’invalidité EDSS avaient une QV significativement meilleure. Ceci était significatif pour quatre des huit domaines SF-36: fonctionnement physique (+22%, p=0.0102), rôle-physique (+100%, p=0.0022), santé générale (+27%, p=0.0070) et fonction sociale (+19%, p=0.0287). La différence moyenne dans la QV était de 8% dans le groupe ayant un EFSS de 3.0 à 6.0 et de 10% dans le groupe dont le score était >6.

Conclusion:

Les patients atteints de formes récurrentes de la SEP qui sont traités par l’IFNB-1b ont une meilleure QV que les patients qui ne sont pas traités, surtout ceux qui ont un EDSS <3.0.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 26 , Issue 4 , November 1999 , pp. 276 - 282
Copyright
Copyright © The Canadian Journal of Neurological 1999

References

1. Weinshenker, BG. Natural history of multiple sclerosis. Ann Neurol 1994;36:S6–S11.CrossRefGoogle ScholarPubMed
2. Brønnum-Hansen, H, Koch-Henriksen, N, Hyllested, K. Survival of patients with multiple sclerosis in Denmark: a nationwide long-term epidemiologic survey. Neurology 1994;44:1901–1907.CrossRefGoogle Scholar
3. Petajan, JH, Gappmaier, E, White, AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996;39:432–441.CrossRefGoogle ScholarPubMed
4. Schipper, H, Clinch, JJ, Olweny, CLM. Quality of life studies: definitions and conceptual issues. In: Spilker, B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996; 11–23.Google Scholar
5. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: Quality of life. Can J Neurol Sci 1998;25:31–38 Google Scholar
6. Ware, JE. The SF-36 health survey. In: Spilker, B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996; 337–345.Google Scholar
7. IQOLASF-36 Standard English (Canada) Version 1.0 – 1994.Google Scholar
8. Vickrey, BG, Hays, RD, Harooni, R, Myers, LW, Ellison, GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187–206.CrossRefGoogle ScholarPubMed
9. Freeman, JA, Langdon, DW, Hobart, JC, Thompson, AJ. Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation. J Neurol Rehab 1996;10:185–194.Google Scholar
10. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655–661.CrossRefGoogle Scholar
11. Paty, DW, Li, DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662–667.CrossRefGoogle ScholarPubMed
12. The IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277–1285.CrossRefGoogle Scholar
13. The PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352: 1498–1504.CrossRefGoogle Scholar
14. Jacobs, LD, Cookfair, DL, Rudick, RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–294.CrossRefGoogle ScholarPubMed
15. Johnson, KP, Brooks, BR, Cohen, JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268–1276.CrossRefGoogle ScholarPubMed
16. The European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–1497.CrossRefGoogle Scholar
17. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part I: Cost of illness. Can J Neurol Sci 1998;25:23–30.CrossRefGoogle Scholar
18. Ware, JE, Snow, KK, Kosinski, M, Gandek, B. SF-36 health survey manual and interpretation guide. Boston: New England Medical Center, The Health Institute, 1993.Google Scholar
19. Ware, JE, Kosinski, M, Bayliss, MS et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care 1995;33(suppl):AS264–AS279.Google Scholar
20. Schwartz, CE, Coulthard-Morris, L, Cole, B, Vollmer, T. The quality-of-life effects of interferon beta-1b in multiple sclerosis. Arch Neurol 1997; 54:1475–1480.CrossRefGoogle ScholarPubMed
21. Parkin, D, Miller, P, McNamee, P, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 1998;2:iii–54.CrossRefGoogle ScholarPubMed
22. Pozzilli, C, Passafiumi, D, Bernardi, S, et al. SPECT, MRI and cognitive functions in multiple sclerosis. J Neurol Neurosurg Psychiatry 1991;54: 110–115.CrossRefGoogle ScholarPubMed
23. Rao, SM, Leo, GJ, Ellington, L, et al. Cognitive dysfunction in multiple sclerosis II. Impact on employment and social functioning. Neurology 1991;41: 692–696.CrossRefGoogle ScholarPubMed
24. Guyatt, GH, Jaeschke, R, Feeny, D, Patrick, DL. Measurements in clinical trials: choosing the right approach. In: Spilker, B, ed. Quality of Life and Pharmacoeconomics in Clinical Trial. 2nd ed. Philadelphia: Lippincott-Raven, 1996; 41–48.Google Scholar